HPLC Purity Testing for Research Peptides, Explained Clearly

Picture a chromatogram: a flat baseline, one tall peak at 11.4 minutes, and a scatter of small peaks on either side. The number printed under it, say 98.7%, is the figure most buyers look at first. HPLC purity testing is the workhorse of peptide quality control, and it is worth knowing how that number is produced, what choices shape it, and where it stops being informative. This article covers the column chemistry, mobile phases, gradients and integration behind a peptide purity figure, then looks at why a tiny copper-binding tripeptide such as GHK-Cu needs a slightly different approach.

How reversed-phase HPLC separates peptides

Reversed-phase HPLC (RP-HPLC) is the dominant mode for synthetic peptides [1, 2]. The stationary phase is silica bonded with hydrophobic alkyl chains, most often C18, sometimes C8 or C4 for larger or more hydrophobic sequences. The mobile phase starts highly aqueous and becomes progressively richer in organic solvent, usually acetonitrile. Peptides bind to the stationary phase through their hydrophobic surface and are released as the organic fraction rises, so elution order roughly tracks overall hydrophobicity.

Peptides behave differently from small molecules on these columns. Retention depends steeply on the percentage of organic modifier, so peptides tend to elute over a narrow band of solvent composition rather than partitioning gradually. That is why gradient elution, not isocratic elution, is the norm, and why small sequence changes, such as a single missing residue, can shift retention enough to separate an impurity from the main peak [2].

A typical analytical method

Most research-grade purity methods look broadly like this:

Parameter	Common choice
Column	C18, 4.6 x 150 or 250 mm, 3 to 5 um particles, 100 to 300 A pores
Mobile phase A	Water + 0.1% TFA
Mobile phase B	Acetonitrile + 0.1% TFA
Gradient	For example 5 to 65% B over 30 min (about 1 to 2% B per minute)
Flow rate	1.0 mL/min
Temperature	25 to 40 C
Detection	UV at 214 or 220 nm

Trifluoroacetic acid does two jobs. It holds the pH near 2, suppressing ionization of carboxyl groups and residual silanols, and it pairs with protonated amines on lysine, arginine and the N-terminus. The net effect is sharper, more symmetrical peaks. Formic acid is the usual substitute when the eluent goes straight into a mass spectrometer, because TFA suppresses electrospray signal, but the trade-off is real: a comparison on five cationic peptides found that TFA-modified mobile phases gave better sensitivity and resolution than formic acid on the same C18 chemistry [3]. The same study showed that particle size and column temperature also changed the impurity profile that was observed [3].

From chromatogram to purity percentage

The purity figure is an area-percent calculation. The data system integrates every peak above a threshold, and purity is the main peak's area divided by the sum of all peak areas. Several decisions sit inside that simple ratio:

• Integration window. Peaks from the solvent front or the column wash at the end of the gradient are usually excluded. Where those limits are drawn changes the denominator.
• Detection threshold. Very small peaks may be ignored if they fall below the integration threshold.
• Co-elution. An impurity that elutes under the main peak is counted as product. Deletion sequences and diastereomers sometimes do exactly this.
• Response factors. Area percent assumes every species absorbs equally per unit mass at the chosen wavelength. At 214 nm this is a reasonable approximation for related peptides, but not an exact one.

Coupling UHPLC to a single-quadrupole mass detector helps with the co-elution problem, because the detector can show whether the main peak contains one mass or several [6]. That is why purity data and mass data are best read together; see our guide to mass spectrometry and peptide identity.

Case study: small polar peptides such as GHK-Cu

Standard C18 gradients are built for peptides of perhaps 5 to 40 residues with some hydrophobic content. Glycyl-L-histidyl-L-lysine (GHK) is the opposite: three residues, two of them basic, and a molecular weight of about 340 Da. Molecules like this are weakly retained on C18 and can elute close to the void volume, where they overlap with salts and other unretained material.

Published analytical work shows how this is handled. A method for GHK and its dipeptide metabolite His-Lys in rat plasma used ion-pair chromatography with 1-pentanesulfonate on a 250 x 4.6 mm C18 column, followed by post-column derivatization with o-phthalaldehyde for sensitive detection [4]. The alkyl sulfonate pairs with the protonated amines and gives the tripeptide enough hydrophobic character to be retained and resolved. The same study noted rapid conversion of GHK to His-Lys in plasma, which is a reminder that the dipeptide is the first degradation product to look for in any GHK sample.

The copper complex adds another layer. GHK binds Cu2+ with an affinity comparable to the copper-transport site of albumin [5]. At the low pH of a TFA mobile phase the complex is expected to dissociate, so a reversed-phase chromatogram of GHK-Cu largely reports on the peptide ligand. Confirming copper stoichiometry calls for a separate measurement, such as elemental analysis, rather than the purity chromatogram alone.

What a purity figure does not tell you

HPLC purity is relative, and several quantities fall outside it:

1. Identity. A pure peak of the wrong molecule still scores 99%.
2. Net peptide content. Counterions (often TFA) and water do not absorb at 214 nm and are not in the calculation.
3. Non-chromophoric or unretained contaminants. Inorganic salts and some small molecules pass through unseen.
4. Method dependence. A purity value only means something alongside the column, gradient and wavelength that produced it.

The practical meaning of different purity tiers is covered in peptide purity grades explained. When we post a chromatogram on our lab reports page, the method conditions are listed with it so the number can be interpreted.

Practical checks for HPLC purity testing reports

• Is the full chromatogram shown, including the start and end of the gradient?
• Is the detection wavelength stated, and is it in the 210 to 220 nm range?
• Is the main peak symmetrical, without shoulders that might hide a co-eluting species?
• Does the peak table add up to the reported percentage?
• For short or very polar peptides, does the method retain the analyte well away from the void volume?

Key takeaways

• RP-HPLC on C18 with water/acetonitrile and 0.1% TFA is the standard purity method for synthetic peptides.
• The purity figure is an area percentage at a UV wavelength, and its value depends on method choices.
• Co-eluting impurities and non-UV-absorbing material are not captured, so pair HPLC with mass spectrometry.
• Small, polar peptides such as GHK may need ion-pairing or other adjustments to be retained and resolved.
• A report is only interpretable if the method conditions accompany the number.

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Aguilar MI. Reversed-phase high-performance liquid chromatography. Methods Mol Biol. 2004;251:9-22. PubMed
2. Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods Mol Biol. 2007;386:3-55. PubMed
3. Stalmans S, Gevaert B, Verbeke F, et al. Quality control of cationic cell-penetrating peptides. J Pharm Biomed Anal. 2015;117:289-297. PubMed
4. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl. 1997;692(1):37-42. PubMed
5. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. PubMed
6. D'Hondt M, Gevaert B, Wynendaele E, et al. Implementation of a single quad MS detector in routine QC analysis of peptide drugs. J Pharm Anal. 2016;6(1):24-31. PubMed